## Anna K Renfrew

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2770892/publications.pdf

Version: 2024-02-01

40 papers

2,572 citations

257450 24 h-index 289244 40 g-index

47 all docs

47 docs citations

47 times ranked

3169 citing authors

#	Article	IF	CITATIONS
1	Warburg Effect Targeting Co(III) Cytotoxin Chaperone Complexes. Journal of Medicinal Chemistry, 2021, 64, 2678-2690.	6.4	9
2	The effect of charge on the uptake and resistance to reduction of platinum( <scp>iv</scp> ) complexes in human serum and whole blood models. Metallomics, 2020, 12, 1599-1615.	2.4	8
3	Metal complexes as a promising source for new antibiotics. Chemical Science, 2020, 11, 2627-2639.	7.4	290
4	Towards Lightâ€Activated Ruthenium–Arene (RAPTAâ€Type) Prodrug Candidates. ChemBioChem, 2019, 20, 2876-2882.	2.6	30
5	Photolabile Ru Model Complexes with Chelating Diimine Ligands for Lightâ€√riggered Drug Release. European Journal of Inorganic Chemistry, 2018, 2018, 1447-1447.	2.0	0
6	Photolabile Ru Model Complexes with Chelating Diimine Ligands for Lightâ€Triggered Drug Release. European Journal of Inorganic Chemistry, 2018, 2018, 1469-1480.	2.0	10
7	Photolabile ruthenium complexes to cage and release a highly cytotoxic anticancer agent. Journal of Inorganic Biochemistry, 2018, 179, 146-153.	3.5	28
8	Harnessing the properties of cobalt coordination complexes for biological application. Coordination Chemistry Reviews, 2018, 375, 221-233.	18.8	84
9	Targeting curcumin to specific tumour cell environments: the influence of ancillary ligands. Metallomics, 2017, 9, 699-705.	2.4	13
10	Photolabile Ruthenium(II)-Purine Complexes: Phototoxicity, DNA Binding, and Light-Triggered Drug Release. European Journal of Inorganic Chemistry, 2017, 2017, 1538-1538.	2.0	0
11	Hypoxia-Responsive Cobalt Complexes in Tumor Spheroids: Laser Ablation Inductively Coupled Plasma Mass Spectrometry and Magnetic Resonance Imaging Studies. Inorganic Chemistry, 2017, 56, 9860-9868.	4.0	34
12	The influence of the ancillary ligand on the potential of cobalt( <scp>iii</scp> ) complexes to act as chaperones for hydroxamic acid-based drugs. Dalton Transactions, 2017, 46, 15897-15907.	3.3	14
13	Photolabile Ruthenium(II)–Purine Complexes: Phototoxicity, DNA Binding, and Lightâ€∢riggered Drug Release. European Journal of Inorganic Chemistry, 2017, 2017, 1679-1686.	2.0	28
14	Spectroscopic Approaches to Tracking Metal-based Drugs in Cells and Tissue. Chimia, 2017, 71, 112.	0.6	4
15	Reversible magnetogenic cobalt complexes. RSC Advances, 2016, 6, 30021-30027.	3.6	19
16	Cobalt(III) Chaperone Complexes of Curcumin: Photoreduction, Cellular Accumulation and Lightâ€Selective Toxicity towards Tumour Cells. Chemistry - A European Journal, 2015, 21, 15224-15234.	3.3	79
17	A luminescent ruthenium(ii) complex for light-triggered drug release and live cell imaging. Chemical Communications, 2015, 51, 14038-14041.	4.1	67
18	Transition metal complexes with bioactive ligands: mechanisms for selective ligand release and applications for drug delivery. Metallomics, 2014, 6, 1324-1335.	2.4	170

#	Article	IF	CITATIONS
19	Delivery and release of curcumin by a hypoxia-activated cobalt chaperone: a XANES and FLIM study. Chemical Science, 2013, 4, 3731.	7.4	130
20	Dual Targeting of Hypoxic and Acidic Tumor Environments with a Cobalt(III) Chaperone Complex. Journal of Medicinal Chemistry, 2012, 55, 11013-11021.	6.4	85
21	Antiproliferative activity of chelating N,O- and N,N-ruthenium(ii) arene functionalised poly(propyleneimine) dendrimer scaffolds. Dalton Transactions, 2011, 40, 1158-1167.	3.3	148
22	Adding diversity to ruthenium(II)–arene anticancer (RAPTA) compounds via click chemistry: The influence of hydrophobic chains. Journal of Organometallic Chemistry, 2011, 696, 772-779.	1.8	42
23	Metabolization of [Ru( $\hat{l}$ -6-C6H5CF3)(pta)Cl2]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand. Journal of Biological Inorganic Chemistry, 2010, 15, 919-927.	2.6	45
24	Synthesis and Anticancer Activity of Long-Chain Isonicotinic Ester Ligand-Containing Arene Ruthenium Complexes and Nanoparticles. Journal of Cluster Science, 2010, 21, 313-324.	3.3	23
25	Discovery, Structure, and Anticancer Activity of an Iridium Complex of Diselenobenzoquinone. Angewandte Chemie - International Edition, 2010, 49, 7530-7533.	13.8	73
26	Synthesis and anticancer activity of chalcogenide derivatives and platinum(II) and palladium(II) complexes derived from a polar ferrocene phosphanyl–carboxamide. Applied Organometallic Chemistry, 2010, 24, 392-397.	3.5	14
27	Synthesis and characterisation of the water soluble bis-phosphine complex [Ru(Î-6-cymene)(PPh2(o-C6H4O)-Î $^{\circ}$ 2-P,O)(pta)]+ and an investigation of its cytotoxic effects. Comptes Rendus Chimie, 2010, 13, 1144-1150.	0.5	14
28	Drug delivery of lipophilic pyrenyl derivatives by encapsulation in a water soluble metalla-cage. Dalton Transactions, 2010, 39, 8248.	3.3	82
29	Use of Perfluorinated Phosphines to Provide Thermomorphic Anticancer Complexes for Heat-Based Tumor Targeting. Inorganic Chemistry, 2010, 49, 2239-2246.	4.0	35
30	Ruthenium(II) Arene Compounds as Versatile Anticancer Agents. Chimia, 2009, 63, 217-219.	0.6	15
31	Arene–ruthenium complexes with ferrocene-derived ligands: Synthesis and characterization of complexes of the type [Ru(Î-6-arene)(NC5H4CH2NHOC-C5H4FeC5H5)Cl2] and [Ru(Î-6-arene)(NC3H3N(CH2)2O2C–C5H4FeC5H5)Cl2]. Journal of Organometallic Chemistry, 2009, 694, 855-861.	1.8	54
32	Anticancer activity of multinuclear arene ruthenium complexes coordinated to dendritic polypyridyl scaffolds. Journal of Organometallic Chemistry, 2009, 694, 3470-3476.	1.8	91
33	Influence of Structural Variation on the Anticancer Activity of RAPTA-Type Complexes: ptn versus pta. Organometallics, 2009, 28, 1165-1172.	2.3	79
34	Soluble Redox-Active Polymetallic Chains [{Ru0(CO)(L)(bpy)}m]n(bpy = 2,2′-bipyridine, L = PrCN, Clâ~;m= 0,)	Tj. <u>F.T</u> Qq0	0 q.rgBT /Ove
35	Tuning the Efficacy of Ruthenium(II)-Arene (RAPTA) Antitumor Compounds with Fluorinated Arene Ligands. Organometallics, 2009, 28, 5061-5071.	2.3	61
36	Synthesis, Molecular Structure, and Anticancer Activity of Cationic Arene Ruthenium Metallarectangles. Organometallics, 2009, 28, 4350-4357.	2.3	118

#	Article	IF	CITATIONS
37	Influence of the Diketonato Ligand on the Cytotoxicities of [Ru(η <sup>6</sup> â€ <i>p</i> êcymene)(R <sub>2</sub> acac)(PTA)] <sup>+</sup> Complexes (PTA =) Tj ETQc	1 <b>2.0</b> .784	  31 <b>&amp;</b> argBT  Ove

The "Complexâ€inâ€aâ€Complex―Cations
[(acac)<sub>2</sub>MâŠ,Ru<sub>6</sub>(<i>p</i>àâ€<i>i</i>PrC<sub>6</sub>H<sub>4</sub>Me)<sub>6</sub>(sub>6</sub)(sub+20x/sub>(acac)<br/>A Trojan Horse for Cancer Cells. Angewandte Chemie - International Edition, 2008, 47, 3773-3776.

39	Water-soluble arene ruthenium complexes containing pyridinethiolato ligands: Synthesis, molecular structure, redox properties and anticancer activity of the cations [(Î-6-arene)Ru(p-SC5H4NH)3]2+. Journal of Organometallic Chemistry, 2008, 693, 3419-3424.	1.8	22
40	An easy electrochemical and chemical synthesis of [Ru(bpy)(CH3CN)2Cl2]: a synthon for heteroleptic tris(diimine) Ru(ii) complexes. Dalton Transactions, 2008, , 5891.	3.3	2